Advertisement
Collaboration › Details
Compugen–Burns McClellan: public relations, 201803– service existent investor relations by Burns McClellan
Period | 2018-03-08 | |
Partner, 1st | Compugen Ltd. (Nasdaq: CGEN) | |
Group | Compugen (Group) | |
Product | public relations / investor relations / marcom (services) | |
Product 2 | cancer immunotherapy (immuno-oncology, I-O) | |
Person | Steier, Jill (Burns McClellan 201803) | |
Compugen Ltd.. (3/8/18). "Press Release: Compugen to Present at the Cowen and Company 38th Annual Health Care Conference". Holon.
Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that Anat Cohen-Dayag, PhD, President and CEO of Compugen, will present a corporate overview and update at the Cowen and Company 38th Annual Health Care Conference in Boston, on Tuesday, March 13, 2018, at 10:40 AM.
A live webcast of the presentation will be available on Compugen’s website. A replay will be available after the presentation ends.
Also at the Cowen Health Care Conference, on March 14, 2018, at 12:45 PM, Charles Drake, MD, PhD, Director, Genitourinary Oncology, Co-Director Immunotherapy Program, Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center and a member of Compugen’s scientific advisory board, will take part in a panel titled “Novel Immuno-Oncology Drug Candidates.”
About Compugen
Compugen is a therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company’s therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered, including T cell immune checkpoints and myeloid target programs. Compugen’s business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with R&D facilities in both Israel and South San Francisco, CA. Compugen’s shares are listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at http://www.cgen.com.
Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972 (3) 765-8124
Investor Relations contact:
Burns McClellan, Inc.
Jill Steier
Email: jsteier@burnsmc.com
Tel: 212-213-0006
Record changed: 2022-11-19 |
Advertisement
More documents for Compugen (Group)
- [1] Dotmatics Ltd.. (3/3/21). "Press Release: Dotmatics Announces Licensing Agreement for Informatics Software with Compugen". Bishop’s Stortford....
- [2] Compugen Ltd.. (11/13/18). "Press Release: Compugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy". Holon....
- [3] Compugen Ltd.. (11/7/18). "Press Release: Compugen Reports Third Quarter 2018 Results". Holon....
- [4] Compugen Ltd.. (4/2/18). "Press Release: Compugen Announces Exclusive License Agreement with MedImmune for the Development of Bi-specific and Multi-specific Antibody Products". Holon....
- [5] Compugen Ltd.. (3/26/18). "Press Release: Compugen Announces Appointment of Henry Adewoye, MD, as Chief Medical Officer". Holon....
- [6] Compugen Ltd.. (3/8/18). "Press Release: Compugen to Present at the Cowen and Company 38th Annual Health Care Conference". Holon....
- [7] Selexis S.A.. (3/7/18). "Press Release: Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of Antibody-Based Therapeutics". Geneva....
- [8] Compugen Ltd.. (11/7/17). "Press Release: Compugen Reports Third Quarter 2017 Results". Holon....
- [9] Compugen Ltd.. (11/6/17). "Press Release: Compugen to Initiate Manufacturing of COM902, Its Lead antiTIGIT Monoclonal Antibody". Holon....
- [10] Compugen Ltd.. (11/2/17). "Press Release: Compugen to Enter Research Collaboration with Mount Sinai on Novel Myeloid Immuno-Oncology Targets". Holon....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top